CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Pfizer Purchase Agreement [Member]	GSK [Member]	Series A, B, C and D Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Pfizer Purchase Agreement [Member]	Common Stock [Member] GSK [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Pfizer Purchase Agreement [Member]	Additional Paid-in Capital [Member] GSK [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balances at Dec. 31, 2020	$ 132,040			$ 3	$ 29			$ 409,722			$ (277,707)	$ (7)
Balance, Shares at Dec. 31, 2020				3,218,287	29,260,247
Issuance of common stock upon the exercise of stock options	1,450							1,450
Issuance of common stock upon the exercise of stock options, shares					160,674
Issuance of common stock and preferred stock net of offering costs and issuance costs	7,831	$ 27,289			$ 1	$ 2		7,830	$ 27,287
Issuance of common stock and preferred stock net of offering costs, shares					475,469	2,362,348
Conversion of convertible preferred stock to common stock, shares				(135)	135,000
Share-based compensation expense	9,430							9,430
Unrealized gain (loss) on available-for-sale securities	5											5
Net loss	(89,756)										(89,756)
Balances at Dec. 31, 2021	88,289			$ 3	$ 32			455,719			(367,463)	(2)
Balance, shares at Dec. 31, 2021				3,218,152	32,393,738
Issuance of common stock upon the exercise of stock options	$ 420							420
Issuance of common stock upon the exercise of stock options, shares	56,120				56,120
Issuance of common stock and preferred stock net of offering costs and issuance costs	$ 14,234		$ 10,278		$ 7		$ 7	14,227		$ 10,271
Issuance of common stock and preferred stock net of offering costs, shares					5,963,294		7,450,000
Conversion of convertible preferred stock to common stock	3			$ (3)	$ 6
Conversion of convertible preferred stock to common stock, shares				(3,218,152)	6,367,000
Share-based compensation expense	9,123							9,123
Unrealized gain (loss) on available-for-sale securities	2											$ 2
IssuanceOfCommonStockUponTheVestingOfRsu	0
Issuance of common stock upon the vesting of RSUs					226,043
Net loss	(46,415)										(46,415)
Balances at Dec. 31, 2022	$ 75,934				$ 52			$ 489,760			$ (413,878)
Balance, shares at Dec. 31, 2022					52,456,195